Microbes4U
Financiado
Study of the therapeutic potential of an Akkermansia muciniphila based products...
Study of the therapeutic potential of an Akkermansia muciniphila based products in subjects with an increased cardio metabolic risk.
Overweight and obesity have reached worldwide epidemic level. Both overweight and obesity are characterized by comorbidities such as cardio-metabolic risk factors (i.e., insulin resistance, type 2 diabetes, hypertension, dyslipide...
Overweight and obesity have reached worldwide epidemic level. Both overweight and obesity are characterized by comorbidities such as cardio-metabolic risk factors (i.e., insulin resistance, type 2 diabetes, hypertension, dyslipidemia, low-grade inflammation) representing a major public health problem. Therefore, it is urgent to find a therapeutic solution to target all these metabolic disorders.
Among the environmental factors able to influence the individual susceptibility to gain weight and to develop metabolic disorders associated with obesity, we have contributed to the demonstration that gut bacteria (i.e, gut microbiota) influence host metabolism.
We recently discovered a putative interesting microbial candidate, namely Akkermansia muciniphila. More exactly, we found that the administration of Akkermansia muciniphila reduced body weight gain, fat mass gain, glycemia, cholesterolemia and inflammatory markers in diet-induced obese mice. Moreover, in overweight/obese patients subjected to a calorie restriction diet, the higher abundance of Akkermansia muciniphila was associated with a better cardio-metabolic status. These observations suggested that the administration of Akkermansia muciniphila in overweight or obese people could be a very interesting therapeutic solution.
Currently, no human study have investigated the beneficial effects of Akkermansia muciniphila administration on obesity and metabolic disorders.
Thus, the main objective of this ERC POC project Microbes4U is to get the proof of concept in humans of the safety and efficacy of Akkermansia muciniphila administration in the treatment of overweight, obesity and metabolic disorders associated such as insulin resistance, type-2 diabetes and dyslipidemia.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2016-06-27
Fecha Fin: 2017-12-31
Fecha Fin: 2017-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2017-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2015:
ERC Proof of Concept Grant
Cerrada
hace 9 años
Presupuesto
El presupuesto total del proyecto asciende a
149K€
Líder del proyecto
UNIVERSITE CATHOLIQUE DE LOUVAIN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.02M€ |
Participante